Online inquiry

IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8173MR)

This product GTTS-WQ8173MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets FCGRT gene. The antibody can be applied in Autoimmune diseases research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8173MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12109MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-003
GTTS-WQ5690MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ15926MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ816MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-085
GTTS-WQ1991MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ901MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-221
GTTS-WQ5232MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ6353MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CSL-362-AML
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW